We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

In this deep dive, BioSpace explores the diverse therapeutic modalities now in development, as well as the opportunities and ...

Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance.

Amgen's new research and development facility in San Francisco. (courtesy photo) Amgen shares saw a slight uptick on March 5 as the company shared the news that it has started two critical late-stage ...

Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...

In an exclusive conversation with Business Today, Camilla Sylvest, Executive Vice President, Commercial Strategy & Corporate ...